Find and Pitch Jounalists, Get Your Story Covered

Tags: biotech biotechnology Cancer drug development Drug prices

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 6 days ago STAT+: Helsinki Declaration says researchers must disclose trial results on a timely basis - 20 days ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 8 months ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - 12 months ago STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs - about 1 year ago STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail - about 1 year ago
2	STAT Staff STAT News Frontiers of health & medicine reporting. healthmedicinejournalism	STAT+: Biotech analyst Brian Skorney and CEO Daphne Zohar weigh in on election results - 9 days ago The biotech updates you need to read this morning - 27 days ago
3	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 9 days ago
4	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 9 days ago
5	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 9 days ago
6	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	The biotech news roundup to start your week - 13 days ago Element Biosciences raises another massive round - 4 months ago The biotech news you missed this week - 4 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 6 months ago New data on liquid biopsy for colorectal cancer detection still underwhelms - 8 months ago Lawmakers want to add more Chinese biotechs to defense list - 8 months ago The need to know biotech news stories today - 9 months ago The Senate health committee looks into its first subpoena in 40 years - 10 months ago The biotech updates you need to read today - 11 months ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - 11 months ago FDA chastens pet companies over antibiotics - 11 months ago The biotech news you missed from the weekend - 11 months ago Novartis is building a new radioligand plant in China - 12 months ago Today’s biotech news roundup, in under 800 words - 12 months ago A new algorithm unveils CRISPR ‘treasure trove’ - 12 months ago These are the need-to-know biotech stories from this weekend - about 1 year ago XBI biotech index rises, giving investors a shred of hope - about 1 year ago Your Monday morning biotech news roundup - about 1 year ago Candor on gene therapy, Abiomed is warned, & BTK success in MS - about 1 year ago Want a biotech buyout? Target cancer - about 1 year ago
7	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago STAT+: Roche’s TIGIT study was a bust. What’s the outlook for its next big bet? - 4 months ago A biotech’s binary bet ends badly - 5 months ago STAT+: The inside story of Enhertu’s pan-tumor approval - 7 months ago STAT+: Weed for weight loss, and more from Biotech Land - 8 months ago STAT+: The biotech scorecard for the first quarter: 17 stock-moving events to watch - 11 months ago
8	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago More evidence on GLP-1s and opioid addiction - about 1 month ago STAT+: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu - 6 months ago
9	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 3 months ago STAT+: Biotech startups post strongest financing numbers in two years - 7 months ago STAT+: A biotech reporter’s notebook: Sunshine rains down on San Francisco - 10 months ago STAT+: Biotech incubator Curie.Bio graduates its first startup - about 1 year ago STAT+: Life science investors close nearly $6 billion in new funds - about 1 year ago STAT+: Life sciences deals on track to hit lowest point since 2017 - about 1 year ago STAT+: What ever happened to biotech’s big comeback? - about 1 year ago
10	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Genentech, a biotech with a storied past, confronts new turbulence in the present - 2 months ago STAT+: With biotech in a slump, the industry’s job market is upside down - 12 months ago STAT+: Failed biotech gives a rare peek inside the tough breaks — and tough choices — that led to its demise - about 1 year ago

Journalists covering biotech reporting